证券简称：三友医疗 证券代码：688085 独立财务顾问报告 目 录 一、释义 ·························································································· 3 二、声明 ·························································································· 4 三、基本假设 ···················································································· 5 四、独立财务顾问意见 ········································································ 6 （一） 对公司实行 2025 年限制性股票激励计划条件的核查意见 ················6 （二） 对 2025 年限制性股票激励计划内容及可行性的核查意见 ················7 ...

注：表格中部分合计数与各明细数直接相加之和在尾数上如有差异，是由于四舍五入所造成。 上海三友医疗器械股份有限公司董事会 | | | | | | 占本激励计 | | | --- | --- | --- | --- | --- | --- | --- | | | | | 获授的限制 | 占授予限制 | | | | 序 | | | | | 划草案公告 | | | 姓名 国籍 | | 职务 | 性股票数量 | | 性股票总数 | | | 号 | | | | | 日公司股本 | | | | | | （万股） | 的比例 | | | | 一、董事、高级管理人员 | | | | | 总额的比例 | | | | 董事、副总裁、首席运 | | | | | | | | 营官 | | | | | | | 董事、高级管理人员小计 | | | | 45.00 | 9.41% | 0.13% | | 二、其他激励对象 | | | | | | | | 核心骨干人员 | | | | | | | （共 53 人） 合计 478.20 100.00% 1.43% 上海三友医疗器械股份有限公司 ...

Group 1 - The company Huayang Intelligent announced a provision for asset impairment of 4.1513 million yuan, which will lead to a reduction in total profit by the same amount for the first half of 2025 [1] - The company's revenue composition for the year 2024 is as follows: motor manufacturing accounts for 88.41%, medical devices for 7.6%, and other businesses for 3.99% [1]

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the employee stock ownership plan and daily related transactions [1][4][8] Group 1: Meeting Details - The meeting is scheduled for September 4, 2025, at 14:30, located at the company's office in Chongqing [4] - The meeting will be conducted both in-person and online, with specific voting times outlined for shareholders [4] - The agenda includes the introduction of attendees, discussion of proposals, and voting on the resolutions [4][8] Group 2: Proposal on Employee Stock Ownership Plan - The company proposes to repurchase and cancel 1,715,024 shares from the 2024 employee stock ownership plan due to unmet performance conditions [8][10] - The repurchase price is set at 8.23 yuan per share, adjusted from the original price of 12.27 yuan per share [10][11] - The funding for the repurchase will come from the company's own funds, and the cancellation will not affect the control of the company [11][12] Group 3: Daily Related Transactions - The company plans to increase the expected amount for daily related transactions in 2025, with a total expected amount of 5,990 million yuan [6][8] - The increase is primarily due to the need to meet procurement demands from related parties [6][7] - The transactions will adhere to fair market pricing principles and will not harm the interests of shareholders [7][8]

西部证券股份有限公司 关于重庆山外山血液净化技术股份有限公司 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，西部证券股份有限公司（以下简称"保荐人"）作为重庆 山外山血液净化技术股份有限公司（以下简称"山外山"、"公司"）持续督导工 作的保荐人，负责山外山上市后的持续督导工作，并出具本持续督导跟踪报告。 一、持续督导工作情况 序号 工作内容 持续督导情况 保荐人己建立健全并有效执行了 建立健全并有效执行持续督导工作制度，并针 对具体的持续督导工作制定相应的工作计划 工作计划 根据中国证监会相关规定，在持续督导工作开 保荐人己与山外山签订《保荐协 始前，与上市公司签署持续督导协议，明确双 议》，该协议明确了双方在持续督 方在持续督导期间的权利义务，并报上海证券 导期间的权利和义务，并报上海 交易所备案 证券交易所备案 保荐人通过日常沟通、定期或不 通过日常沟通、定期回访、现场检查、尽职调 定期回访、现场检查等方式，了解 查等方式开展持续督导工作 山外山业务情况，对山外山开展 持续督导工作 持续督 ...

Core Viewpoint - The report outlines the ongoing supervision and assessment of Hangzhou Anjisi Medical Technology Co., Ltd. by CITIC Securities, focusing on the company's compliance, financial performance, and potential risks in the medical device industry [1][2]. Group 1: Continuous Supervision Overview - CITIC Securities conducted a site inspection on July 14, 2025, as part of its ongoing supervisory responsibilities [1]. - The supervision included reviewing corporate governance documents, financial management systems, and fundraising management practices [1]. Group 2: Identified Issues and Rectification - No major issues were found during the supervision period, indicating effective management practices [2]. - The company faces core competitiveness risks due to the lengthy and complex nature of developing minimally invasive endoscopic devices [2][3]. Group 3: Major Risk Factors - The company is exposed to operational risks from increasing competition in the domestic market and potential price reductions due to healthcare cost control measures [2][4]. - Quality control is critical, as any product defects could harm the company's reputation and financial performance [3][4]. Group 4: Financial Performance - For the first half of 2025, the company reported a revenue of 302.43 million yuan, a 14.56% increase from the previous year [11]. - The total profit for the same period was 149.13 million yuan, reflecting a 2.78% increase [11]. - The net profit attributable to shareholders was 111.51 million yuan, showing a decrease of 7.06% when excluding non-recurring gains [11]. Group 5: Research and Development - The company has increased its R&D investment, with total R&D expenses reaching 34.46 million yuan, a 33.29% increase compared to the previous period [18]. - R&D efforts focus on innovative diagnostic and therapeutic devices, with a strong emphasis on integrating AI technologies [12][18]. Group 6: Market Dynamics - The company is expanding its market presence, with significant sales growth in Europe (38.28%) and Asia (29.05%), while facing a decline in North America (9.89%) due to trade tensions [16]. - The company actively adapts to new procurement policies and payment regulations in the healthcare sector to maintain competitiveness [8][9]. Group 7: Compliance and Governance - The company adheres to various international and domestic quality management standards, ensuring compliance in its operations [13]. - There were no significant violations of fundraising regulations during the supervision period, indicating sound financial governance [21][24].

本公司及董事会全体成员保证公告内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、被实施其他风险警示暨可能被实施退市风险警示的相关情况 公司董事会对众华出具无法表示意见的内部控制审计报告涉及的事项高度 重视，积极采取相应的措施，尽快消除相关事项及其影响。结合公司的实际情况， 公司已采取和拟采取的措施如下： 证券代码：300326 证券简称：ST 凯利 公告编号：2025-084 上海凯利泰医疗科技股份有限公司 上海凯利泰医疗科技股份有限公司（以下简称"公司"）2024年度财务报告 内部控制被众华会计师事务所（特殊普通合伙）（以下简称"众华"）出具了无 法表示意见的审计报告。根据《深圳证券交易所创业板股票上市规则》（以下简 称"《创业板股票上市规则》"）第9.4条第（四）项规定，公司出现"（四） 最近一个会计年度财务报告内部控制被出具无法表示意见或者否定意见的审计 报告，或者未按照规定披露财务报告内部控制审计报告"的情形，公司股票交易 被深圳证券交易所实施其他风险警示；根据《深圳证券交易所创业板股票上市规 则》第 10.4.4 条第（五）项规定，上市公司出现"首个会计年度财务报告内部 控制被出具 ...

浙江拱东医疗器械股份有限公司 2025 年半年度报告 公司代码：605369 公司简称：拱东医疗 浙江拱东医疗器械股份有限公司 浙江拱东医疗器械股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人施慧勇、主管会计工作负责人朱勇及会计机构负责人（会计主管人员）尤志仁 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的经营计划、发展战略、未来计划等前瞻性陈述不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间 的差异。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告 ...

Core Viewpoint - Zhejiang Gongdong Medical Devices Co., Ltd. reported a slight increase in revenue but a significant decline in profit for the first half of 2025, indicating potential challenges in operational efficiency and profitability [1]. Financial Summary - Total assets at the end of the reporting period reached approximately 2.12 billion RMB, an increase of 8.73% compared to the end of the previous year [1]. - Operating revenue for the period was approximately 556.92 million RMB, reflecting a modest increase of 0.58% year-on-year [1]. - Total profit for the period was approximately 55.86 million RMB, showing a substantial decrease of 47.86% compared to the same period last year [1]. - Net profit attributable to shareholders was significantly lower, with a basic earnings per share of 0.23 RMB, down 46.51% from 0.43 RMB in the previous year [1]. - The weighted average return on net assets decreased to 2.91%, down 2.76 percentage points from the previous year [1]. Shareholder Information - The largest shareholder, Shi Huiyong, holds 50.27% of the shares, followed by Shi Yibei with 7.47% [2]. - Other notable shareholders include Taizhou Jinch Investment Management Partnership and several individuals with smaller stakes [2]. - There are noted relationships among major shareholders, indicating potential unified actions in decision-making [3].

Group 1 - The third meeting of the supervisory board of Zhejiang Gongdong Medical Instrument Co., Ltd. was held on August 25, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1][2] - The supervisory board approved the proposal regarding the company's 2025 semi-annual report and its summary, with a unanimous vote of 3 in favor [1][2] - The supervisory board also approved the proposal to cancel the supervisory board and amend the company's articles of association, which will require further approval from the shareholders' meeting [2]